Kevin J. Burns

Associate

kevin.burns@icemiller.com
317 221 2880

Kevin Burns is an associate in Ice Miller's Business Group, where he focuses his practice on mergers and acquisitions, private equity and venture capital transactions. He works with both private equity clients and strategic investors in complex transactions involving mergers, acquisitions and recapitalizations. Kevin also counsels new and emerging companies, assisting in corporate entity selection and formation, drafting corporate governance documents and the creation of bespoke agreements for companies in niche industries.

Prior to joining Ice Miller, Kevin practiced business law in Indianapolis at a firm where he focused on private equity and strategic M&A transactions, securities offerings and general corporate work. Prior to attending law school, Kevin was a United States Peace Corps Volunteer stationed in Bulgaria.

Kevin is licensed to practice in the state of Indiana.

Services & Industries

- Business
- Finance
- Mergers & Acquisitions
- Private Equity

Education

- Indiana University (B.A., 2009)
  - Political Science
- Indiana University Robert H. McKinney School of Law (J.D., 2017)

Admissions

- Indiana

Success Stories

Ice Miller Represents Forge Biologics in $620M Acquisition by Ajinomoto
Forge Biologics Holdings, LLC, a Columbus, Ohio-based premier gene therapy contract development & manufacturing organization, has been acquired by the Ajinomoto Group, a Japanese multinational food and biotechnology public company, in an all-cash $620M deal.

The Ice Miller deal team was led by Edward Braum and Dann Bruno, with additional

corporate support from
Erik Olson, Kevin Burns, Ben Goodman, Chris Michael, Chelsea Abramowitz, Brigid Sharek, Huidi Shu, and Lisa Samblanet. Kathleen Scheidt, Dan Corsaro, Nick Casto, Sean Kim, Holly Banta, Cathy Strauss, Anthony Aaron, Grace Dahm, Nick Reuhs, and Brian Harvey provided specialist support.

Ice Miller has represented Forge since its inception in 2020 through its various rounds of venture capital financing, including its $40M Series A financing in 2020, $120M Series B financing in 2021, and $90M Series C financing in 2022. Ice Miller Business Group partners Edward Braum and Sean Kim have represented Forge through its growth, with Ed overseeing the structuring and financing of the company, and Sean facilitating licensing and day-to-day commercial transactions.

This representation further highlights Ice Miller's rapidly growing life sciences practice, with the acquisition placing Forge in a position for long-term growth. The transaction also supports Ajinomoto's desire to extend its development and manufacturing of gene therapies worldwide.